Biomarker Testing in NSCLC: Best Practices for Personalized Medicine
Panelists discuss how the interpretation of HER2 IHC scores informs treatment decisions in NSCLC, including adherence to ASCO/CAP guidelines and strategies for managing equivocal results.
- (Rohit asks Levy) How do you interpret HER2 IHC scores when determining treatment for patients with NSCLC? How does this influence your therapeutic decisions?
- When applying HER2 scoring and considering ASCO/CAP guidelines in NSCLC, do you follow breast cancer scoring guidelines, or have you considered using gastric cancer scoring?
- How do you interpret equivocal or borderline results? Are there any specific considerations or additional testing you recommend for this group?
Recent Videos
Related Content
